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Aminoglycoside acetyltransferases are important determinants of resistance to
aminoglycoside antibiotics in most bacterial genera. In mycobacteria, however,
aminoglycoside acetyltransferases contribute only partially to aminoglycoside
susceptibility since they are related with low level resistance to these antibiotics
(while high level aminoglycoside resistance is due to mutations in the ribosome).
Instead, aminoglycoside acetyltransferases contribute to other bacterial functions, and
this can explain its widespread presence along species of genus Mycobacterium. This
review is focused on two mycobacterial aminoglycoside acetyltransferase enzymes.
First, the aminoglycoside 2′-N-acetyltransferase [AAC(2′)], which was identified as a
determinant of weak aminoglycoside resistance in M. fortuitum, and later found to be
widespread in most mycobacterial species; AAC(2′) enzymes have been associated
with resistance to cell wall degradative enzymes, and bactericidal mode of action
of aminoglycosides. Second, the Eis aminoglycoside acetyltransferase, which was
identified originally as a virulence determinant in M. tuberculosis (enhanced intracellular
survival); Eis protein in fact controls production of pro-inflammatory cytokines and other
pathways. The relation of Eis with aminoglycoside susceptibility was found after the
years, and reaches clinical significance only in M. tuberculosis isolates resistant to the
second-line drug kanamycin. Given the role of AAC(2′) and Eis proteins in mycobacterial
biology, inhibitory molecules have been identified, more abundantly in case of Eis.
In conclusion, AAC(2′) and Eis have evolved from a marginal role as potential drug
resistance mechanisms into a promising future as drug targets.
Keywords: mycobacteria, aminoglycoside antibiotics, aminoglycoside acetyltransferase, drug target,
pathogenicity, aminoglycoside resistance
BACTERIAL RESISTANCE TO AMINOGLYCOSIDE ANTIBIOTICS
Aminoglycoside (AG) antibiotics (Box 1) have not been an exception to the fact that after their
introduction in clinical practice, resistance has been recorded (Waglechner and Wright, 2017).
In fact, the three classes of aminoglycoside-modifying enzymes, aminoglycoside acetyltransferases
(AACs), aminoglycoside phosphotransferases (APHs), and aminoglycoside nucleotidyltransferases
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(ANTs), have been widely detected in most pathogenic bacteria as
a major determinant of resistance; in these bacteria the presence
of aminoglycoside-modifying enzymes correlated with patterns
of AG susceptibility (Smith and Baker, 2002). The modified
AG (either by acetylation, phosphorylation or nucleotidylation)
fails to inhibit their bacterial target, the 30S ribosomal subunit
(Smith and Baker, 2002). Most genes encoding aminoglycoside-
modifying enzymes are plasmid-located (indicative of a potential
acquisition by horizontal gene transfer processes) and confer the
bacterial hosts with high levels of AG resistance (Davies and
Wright, 1997).
In mycobacteria, however, resistance to AGs resulted mainly
from mutations of the ribosome components that prevent the
drugs from inhibiting its function (Jugheli et al., 2009; Zhang and
Yew, 2009; Shcherbakov et al., 2010). This is due to the fact that
most mycobacterial species have either one (like Mycobacterium.
tuberculosis) or two (like Mycobacterium fortuitum) ribosomal
operons, hence making dominant those mutations acquired in
their components (Magnet and Blanchard, 2005; Shi et al., 2013).
The presence of aminoglycoside-modifying enzymes, mostly
AAC, in mycobacterial species has been reported over the years
(as detailed in the following sections), and the role of such
AACs has been explored, originally for their contribution to AG
resistance, and more recently for their role in other bacterial
processes, which has resulted in the interest of developing
inhibitors of these enzymes (Jana and Deb, 2005; Labby and
Garneau-Tsodikova, 2013). In this review, we will summarize
major findings on two mycobacterial AACs, the AAC(2′)-I and
Eis enzymes, that have resulted in a Copernican turn for AACs in
mycobacteria, from being putative drug resistance mechanisms,
to reach the status of novel drug targets.
AACs IN NON-TUBERCULOUS
MYCOBACTERIA
The first detection of AACs in mycobacteria (Hull et al.,
1984) was reported in a group of M. fortuitum isolates, an
opportunistic fast-growing mycobacteria. Biochemical assays of
crude extracts from M. fortuitum strains revealed the presence
of AAC activity, strongly acetylating gentamicin and kanamycin
A, along with other AGs. This substrate profile was consistent
with that of AAC(3) enzymes that had been previously described
in Pseudomonas and Enterobacteriaceae (Angelatou et al., 1982),
although confirmation at the genetic or molecular levels were
not done at that time. Surprisingly, the AG susceptibility profile
of M. fortuitum could not be correlated with the activity of
AACs, indicating that in this species AACs were not the major
responsible for AG resistance; it was neither correlated with
the presence of plasmids, hence suggesting a chromosomal
location (Hull et al., 1984). In fact, the frequency of resistant
mutants to kanamycin and amikacin in M. fortuitum and the
related species Mycobacterium chelonae ranged between 10−4
and 10−7 (Wallace et al., 1985). This relatively high frequency
of mutations, along with the fact that AAC activity was detected
at similar levels between susceptible and resistant strains, led
the authors to suggest that ribosome alterations were the main
factor responsible of AG resistance in these species (Wallace et al.,
1985). In another study (Udou et al., 1986), altered transport
or permeability of AGs was identified as a contributor to AG
resistance in M. fortuitum, since ribosomes from a clinical isolate
were inhibited by one tenth of the MIC of AGs: for example,
the MIC of kanamycin for M. fortuitum was 50 µg/ml, and in
cell-free systems, 5 µg/ml of kanamycin reduced the activity of
ribosomes to 13% in comparison with drug-free controls; similar
results were obtained when using gentamicin or paromomycin
(Udou et al., 1986).
The biochemical analysis of crude extracts from other non-
tuberculous mycobacteria such as Mycobacterium smegmatis,
Mycobacterium phlei,Mycobacterium vaccae, andMycobacterium
kansasii, from both clinical and environmental origins, revealed
similar characteristics to those found in M. fortuitum: crude
extracts from all strains contained AAC enzymatic activity, but
no correlation with AG susceptibility profile could be established
(Udou et al., 1987; Ho et al., 2000). In other mycobacterial species
such as Mycobacterium avium and Mycobacterium intracellulare,
however, AAC activity could not be detected (Ho et al., 2000).
In a recent study, using cell-free translation assays, ribosomes
of Mycobacterium abscessus and M. smegmatis were inhibited
by both AGs having a 2′-amino group (tobramycin, dibekacin,
and kanamycin B) and by those having a 2′-hydroxyl group
(amikacin, and kanamycin A). However, in M. abscessus, those
AGs having a 2′-amino group (tobramycin, dibekacin, and
kanamycin B) were less efficient in killing the cells and inhibiting
its ribosomes, which is consistent with the presence of a
highly active AAC(2′) activity in this species. These findings
suggested that in M. abscessus, AACs could somewhat mitigate
the bactericidal effect of its AGs substrates (Maurer et al., 2015).
Interestingly, when characterizing the enzymatic activity of
crude extracts, early reports detected that substrates such as
amino sugars, malonyl-CoA, propionyl-CoA or butyryl-CoA
inhibited the enzymatic activity of AACs from mycobacterial
species. Such effect of non-acetyl CoA donors had never been
described for the AAC(3) enzymes from other bacteria (Udou
et al., 1987). Altogether, these findings strongly suggested for the
very first time that, in mycobacteria, AACs could have important
metabolic functions, and their contribution to AG resistance
could be marginal (Udou et al., 1989).
AAC(2′), A NEW ENZYME COMES INTO
SCENE
In Providencia stuartii, a Gram-negative species, phylogenetically
distant from mycobacteria, a novel class of AAC was identified
as AAC(2′), because of its acetylating activity against gentamicin
and lack of enzymatic activity against kanamycin A. The gene
encoding AAC(2′)-Ia was cloned from P. stuartii (Rather et al.,
1993) and found to be present in the chromosome of all isolates
of this bacteria. In P. stuartii, the expression of the aac(2′)-
Ia gene was controlled by several transcriptional regulators
(Macinga and Rather, 1999), suggesting that this enzyme could
play an important role, beyond its contribution to drug resistance
(Franklin and Clarke, 2001). In fact, AAC(2′)-Ia contributes to
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BOX 1 | Aminoglycosides: origins, structure, mode of action, resistance and clinical use.
Most aminoglycoside antibiotics are produced by bacterial species of the genus Streptomyces, such as the antitubercular streptomycin that is produced by
S. griseus being the first antibiotic identified from bacteria. Other genera producing aminoglycosides are Micromonospora and Bacillus. Many semi-synthetic
aminoglycosides, such as amikacin, have also been produced (Mingeot-Leclercq et al., 1999; Magnet and Blanchard, 2005; Shi et al., 2013).
Structurally, aminoglycosides are formed by an aminocyclitol (commonly, 2-deoxystreptamine) with additional amino sugars bound by glycosidic bonds. There are
two large families of 2-deoxystreptamine aminoglycosides, those carrying substitutions at positions 4 and 5 of the 2-deoxystreptamine ring (including neomycin,
paromomycin, lividomycin, ribostamycin and butirosin) and those being substituted at positions 4 and 6 of the 2-deoxystreptamine (including kanamycin, amikacin,
tobramycin, dibekacin, arbekacin, gentamicin, isepamicin, sisomicin, and netilmicin). The carbon atoms in the sugar bound to position 4 of the 2-deoxystreptamine
ring are named with primed numbers (’), and those in the sugar bound to positions 5 or 6 of the 2-deoxystreptamine ring are named with double-primed numbers (”).
Other aminoglycosides contain aminocyclitols distinct to 2-deoxystreptamine (this is the case of streptomycin or apramycin) or are formed by fused amino sugar
rings (i.e., spectinomycin) (Magnet and Blanchard, 2005; Shi et al., 2013). The following figure shows the structure of kanamycin A, an example of 4,6 di-substituted
2-deoxystreptamine aminoglycoside antibiotic.
The bacterial target of aminoglycosides is the 30S small ribosomal subunit, and their global effect is the interference with protein synthesis. In bacterial cells,
translation is initiated when the 30S ribosomal subunit binds the Shine-Dalgarno sequence (because of sequence complementarity between the Shine-Dalgarno
sequence and the 16S rRNA molecule of the 30S ribosomal subunit), which is normally present in the 5′ untranslated region of mRNAs. Next, initiation factors and
fMet-tRNA will join the complex that finally will recruit the 50S ribosomal subunit in order to start translation. Aminoglycoside binding to the 30S subunit does not
affect the binding of mRNA and the large 50S subunit, so translation can proceed. However, aminoglycosides differ in their binding site at the 30S subunit, hence
affecting the protein production at different levels. Whereas spectinomycin blocks translocation (hence being bacteriostatic), streptomycin and most
2-deoxystreptamine aminoglycosides lock the ribosome in a conformation that is prone to introducing erroneous aminoacyl-tRNAs. The accumulation of aberrant
proteins in the bacteria results in cell death (Davies and Wright, 1997; Magnet and Blanchard, 2005; Shell et al., 2015).
Resistance to aminoglycosides may be due to several mechanisms (Davies and Wright, 1997; Magnet and Blanchard, 2005). Reduced uptake (which can be a
consequence of alterations in the composition of bacterial membrane or to metabolic conditions like anaerobiosis) or the action of efflux pumps can lead to limited
intracellular concentration of aminoglycosides, hence causing resistance. Mutations in 16S ribosomal RNA or certain ribosomal proteins such as S12 (encoded by
rpsL gene) lead to aminoglycoside resistance through target modification; this is also achieved after the action of methyltransferases, which introduce methyl groups
in guanine or adenine nucleotides of 16S ribosomal RNA. The presence of aminoglycoside-modifying enzymes is, however, the most prevalent mechanism of
aminoglycoside resistance; there are three types of aminoglycoside-modifying enzymes: aminoglycoside N-acetyltransferases (AAC), O-phosphotransferases (APH),
and O-nucleotidyltransferases (ANT). Aminoglycoside-modifying enzymes are named by using the aforementioned abbreviations, followed by a number in brackets
indicating the site of modification in the aminoglycoside molecule (as explained above), a Roman numeral related with substrate profile, and a lower-case letter for
differentiating isoenzymes, i.e., AAC(2′)-Ib.
Clinically, due to their oto- and nephrotoxicity and the rising prevalence of resistance, aminoglycosides are commonly reserved as a second line of treatment of
serious infections. Due to their low absorption when given orally, aminoglycosides need to be administered through injections. Streptomycin was a first-line drug in
the treatment of tuberculosis, and in our days, kanamycin and amikacin are listed as second line drugs against this disease. Spectinomycin is used against Neisseria
gonorrhoeae infections (Suay-Garcia and Perez-Gracia, 2018). Pseudomonas aeruginosa infections in cystic fibrosis patients, septicemia, endocarditis and several
other infections caused by non-tuberculous mycobacteria, Gram-positive or Gram-negative bacteria can be treated efficiently by using aminoglycosides, either alone
or in combinations with other antibacterials such as the beta-lactam antibiotics (Mingeot-Leclercq et al., 1999; Magnet and Blanchard, 2005; Bassetti et al., 2018).
O-acetylation of peptidoglycan affecting cell morphology and the
expression of autolysins, and can use acetylated peptidoglycan
precursors as donors of acetyl groups, another indication about
the role of this enzyme beyond resistance (Payie et al., 1995, 1996;
Clarke et al., 1996; Payie and Clarke, 1997).
AAC(2′) in Mycobacteria
Given the high AG acetylating activity against gentamicin,
tobramycin, netilmicin and its derivatives 2′-N-ethyl- and
6′-N-ethyl-netilmicin, kanamycin A and kanamycin B found in
M. fortuitum (Hull et al., 1984; Ainsa et al., 1996), we launched
a molecular approach aimed at characterizing the determinant of
AG resistance in this species. A genomic library of M. fortuitum
was transformed in M. smegmatis, and characterization of AG
resistant clones allowed the identification of a M. fortuitum
gene showing sequence similarity to aac(2′)-Ia of P. stuartii.
The enzyme of M. fortuitum was named AAC(2′)-Ib (Ainsa
et al., 1996) and was capable of acetylating gentamicin, but
not kanamycin A, hence indicating that another AAC enzyme
should be present in M. fortuitum. Similarly to P. stuartii,
the aac(2′)-Ib gene was found in all strains of M. fortuitum
regardless of the phenotype of AG resistance, suggesting other
roles for the AAC(2′)-Ib in this species. Further studies (done
by database searching or by southern blot analysis using the
probe of aac(2′)-Ib gene) demonstrated the presence of aac(2′)-
I genes in other mycobacterial species, including M. tuberculosis
(the major pathogenic species in this genus), Mycobacterium
leprae, and M. smegmatis, indicating thus that the presence
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of aac(2′)-I genes in mycobacteria could be universal (Ainsa
et al., 1997). Interestingly, the expression of the aac(2′)-Id gene
in M. smegmatis was driven from two promoters, and the
strongest one produced a leaderless transcript having a GTG
translation start codon at its 5′ end (Mick et al., 2008). Leaderless
transcripts are those in which the transcription start site coincides
with the translation start codon; although representing a rather
unusual feature in the model organism E. coli, they are quite
common in mycobacteria, where 25% of all transcripts are
predicted to be leaderless (Shell et al., 2015); in fact, eis gene
of M. tuberculosis (see the section “The Eis Protein Becomes a
Novel Aminoglycoside Acetyltransferase,” below) is transcribed
also as a leaderless mRNA (Zaunbrecher et al., 2009). In leaderless
mRNAs, there is no Shine-Dalgarno sequence, and 70S ribosomes
bind directly to the 5′-end of the mRNA in order to initiate
translation (Shell et al., 2015).
New Roles for AAC(2′) in Mycobacteria
Two major evidences supported that in mycobacteria, AAC(2′)-
I enzymes could have additional roles other than acetylation of
AGs containing 2′-amino group: first, the capability of amino
sugars and diverse acyl-CoA molecules to inhibit the acetylating
activity of mycobacterial crude extracts (Udou et al., 1989); and
second, the implication of AAC(2′)-Ia (an enzyme of the same
class) in acetylation of cell wall substrates in P. stuartii. In a series
of laboratory mutants of P. stuartii expressing aac(2′)-Ia gene
at different levels, it was found that the extent of peptidoglycan
acetylation correlated with the activity of AAC(2′)-Ia, hence
suggesting a partial contribution of this enzyme (along with other
enzymes) to peptidoglycan acetylation. Many bacterial pathogens
acetylate their peptidoglycan as a way to resist the action of
muramidase enzymes. Under in vitro conditions, AAC(2′)-Ia was
able to acetylate tobramycin having acetylated peptidoglycan as
donor of acetyl groups (Payie et al., 1995, 1996; Payie and Clarke,
1997).
We investigated the hypothesis of mycobacterial AAC(2′)-I
enzymes having also a role in cell wall metabolism, and a gene
knock-out mutant of M. smegmatis deleted in aac(2′)-Id gene was
constructed. This mutant (named EP-10) defective in AAC(2′)-
I activity was more susceptible to gentamicin, tobramycin,
dibekacin, and netilmicin than the parental wild-type strain, and
crude extracts of M. smegmatis EP-10 failed to acetylate 2′-amino
group containing AGs, whereas wild-type strains of M. smegmatis
readily acetylated such AGs (Ainsa et al., 1997; Maurer et al.,
2015). M. smegmatis EP-10 was also twofold more susceptible
to lysozyme, a feature that has been associated with the extent
of peptidoglycan acetylation (Ainsa et al., 1997). Hence, we
concluded that in M. smegmatis, AAC(2′)-Id enzyme could also
contribute to acetylation of peptidoglycan, since a less extensively
acetylated peptidoglycan in the knock-out strain would be more
susceptible to lysozyme degradation affecting cell viability.
Biochemical Analysis of Mycobacterial
AAC(2′)-I Enzymes
The presence of an AG (2′)-N-acetyltransferase gene in the
genome of M. tuberculosis was intriguing. In this species, AAC
activity had never been reported (Mitsuhashi et al., 1977) and
the expression of the aac(2′)-Ic gene [annotated as Rv1258c gene
in the M. tuberculosis H37Rv genome (Cole et al., 1998)] in the
surrogate host M. smegmatis could not be associated with any
change in the levels of susceptibility to AGs (Ainsa et al., 1997).
We constructed a knock-out mutant of M. tuberculosis H37Rv
deleted in the aac(2′)-Ic gene and observed that the mutant
(named M. tuberculosis B1) was twofold more susceptible than
the original wild-type strain to AGs containing a 2′-amino group
such as gentamicin, tobramycin and dibekacin, and fourfold
more susceptible to 6′-N-ethyl-netilmicin. This indicated that
the aac(2′)-Ic gene was being expressed in M. tuberculosis
although at a very low level, and that the AAC(2′)-Ic enzyme in
M. tuberculosis would acetylate all these four AGs in the wild type
strain; hence, acetylated AGs would bind less efficiently to the
ribosome, and the AAC(2′)-Ic enzyme would contribute to basal
AG resistance in this species.
In order to find the physiological role of this enzyme
in M. tuberculosis, recombinant E. coli-produced AAC(2′)-Ic
enzyme from M. tuberculosis was studied and found to efficiently
acetylate AG antibiotics containing an amino group at the 2′
position (as expected; for example, Km for kanamycin B was
1.4 µM), and surprisingly, it was also capable of acetylating
(although to a much lesser extent) other AGs such as kanamycin
A (Km 320 µM) and amikacin (Km 968 µM) that have a
hydroxyl group in the 2′ position, hence suggesting this enzyme
to be capable of both N- and O-acetylation (Hegde et al.,
2001; Draker et al., 2003). This residual activity of AAC(2′)-
Ic against kanamycin A and amikacin does not affect their
bactericidal activity, and these two antibiotics are used as second
line drugs against drug resistant M. tuberculosis (World Health
Organization [WHO], 2010). The activity of M. tuberculosis
AAC(2′)-Ic is dependent on metal ions, being inhibited by Cu2+
and Au3+ (Li et al., 2015).
Another study consisted in binding covalently the AGs
kanamycin A, tobramycin, neamine and neomycin B to an
agarose matrix in order to quantify the extent of AG acetylation
by AAC enzymes and their subsequent ability to bind an artificial
probe mimicking the A-site of the ribosome (Barrett et al.,
2008). In such experimental model system, the AGs acetylated by
M. tuberculosis AAC(2′)-Ic enzyme (only tobramycin, neamine
and neomycin B) maintained their binding affinity with the
probe mimicking A-site of the ribosome at detectable levels,
maybe because the percent of AG acetylation by AAC(2′)-Ic was
low. In contrast, these AGs were very efficiently acetylated by
E. coli AAC(3) (at a different amino group) and had readily lost
their affinity for binding this artificial probe. These experiments
suggested that subtle differences in the structure of modified
AGs (i.e., acetylation at the amino group in 2′ or 3 position) are
sufficient to drastically affect their capability of binding to the
A-site probe, and this would be expected to correlate with their
activity as ribosome inhibitors. In consequence, in mycobacteria,
AAC(2′)-I enzymes would not play a major role in resistance
to these drugs (Barrett et al., 2008). High resolution crystal
structures of AAC(2′)-Ic complexed with AGs demonstrated
that this enzyme is a member of the GNC5 acetyltransferase
superfamily and suggested a role in the synthesis of mycothiol,
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a metabolite that has a key role in regulating redox potential in
mycobacteria (Vetting et al., 2002, 2003).
In agreement with the preferential N-acetylating activity over
the O-acetylating activity that was found in the M. tuberculosis
enzyme (Hegde et al., 2001; Draker et al., 2003), M. abscessus
clinical isolates were found to be more susceptible to AGs
containing a hydroxyl group at the 2′ position (such as amikacin
and kanamycin A) than to AGs with a 2′-amino group (such
as tobramycin, dibekacin and kanamycin B), as the latter group
would be substrates of M. abscessus AAC(2′)-I enzyme (Maurer
et al., 2015). In fact, crude extracts of M. abscessus efficiently
acetylated kanamycin B, whereas kanamycin A was not acetylated
at detectable levels. In this species, deletion of the aac(2′)-I gene
resulted in increased susceptibility to kanamycin B, tobramycin,
dibekacin and gentamicin C (all of them containing a 2′-amino
group) (Rominski et al., 2017). These two reports demonstrate
that in M. abscessus, the presence of an AAC(2′)-I enzyme
contributes to decreased innate susceptibility to AGs containing
a 2′-amino group (Luthra et al., 2018).
Becoming a Drug Target: Developing
Inhibitors of AAC(2′)-I
The interest in developing inhibitors against AAC(2′)-I enzymes
came from a study in the non-tuberculous species M. abscessus
(Maurer et al., 2014). It was found that AGs such as amikacin,
gentamicin or tobramycin, which are normally bactericidal
against E. coli, do not have such activity against M. abscessus
or M. smegmatis. However, disruption of the chromosomally
encoded aac(2′)-I gene in these species restored the bactericidal
activity of these AGs (Maurer et al., 2014). Given that AGs
are used as second-line drugs in treatment of multidrug
resistant (MDR) tuberculosis infections, and also in the treatment
of other infections caused by non-tuberculous mycobacteria,
the possibility of developing compounds that could enhance
bactericidal activity of current antimycobacterial treatments
became an interesting approach.
To date, the only putative inhibitor of M. tuberculosis
AAC(2′)-Ic is andrographolide, a natural product that was
identified in methanolic extracts of a plant that were capable
of inhibiting growth of M. tuberculosis strains (Prabu et al.,
2015). In silico analysis predicted that this compound could
potentially bind with a high affinity the AAC(2′)-Ic enzyme, as
well as isocitrate lyase (a metabolic enzyme of the glyoxylate
shunt, involved in persistence and virulence of M. tuberculosis)
and other M. tuberculosis proteins (Prabu et al., 2015). However,
the specificity of this binding and the ability to really inhibit
such putative target proteins were not tested. Given that the
gene encoding AAC(2′)-Ic is not essential in M. tuberculosis, a
direct link between AAC(2′)-Ic inhibition and bacterial growth
inhibition could be discarded. Hence, the ability of plant extracts
containing andrographolide to inhibit growth of M. tuberculosis
could be due to the presence of additional compounds in
the extract, or to multiple effects on M. tuberculosis cells.
Other in silico analysis revealed that AAC(2′)-Ic enzyme from
M. tuberculosis could interact with ten other proteins (including
a protein of a putative RND-like efflux pump), suggesting that
inhibition of AAC(2′)-Ic could also impact many other metabolic
processes, hence conferring this enzyme with a relevant role in
drug discovery of antituberculosis agents (Joshi et al., 2013).
THE Eis PROTEIN BECOMES A NOVEL
AMINOGLYCOSIDE
ACETYLTRANSFERASE
Investigation of M. tuberculosis virulence factors lead to the
identification of a protein, that was required for infecting and
survival in human macrophages; this protein was named Eis
for enhanced intracellular survival (Box 2) (Wei et al., 2000).
Bioinformatic analysis revealed that Eis protein of M. tuberculosis
was an acetyltransferase of the GCN-5 family (Samuel et al.,
2007).
Later on, the analysis of kanamycin resistant M. tuberculosis
laboratory and clinical strains revealed mutations in the−10 and
−35 regions of the eis gene promoter, which resulted in increased
levels of eis mRNA and Eis protein. These mutations were related
to low-level resistance to kanamycin (MIC 25 µg/ml), but not to
amikacin (MIC < 4 µg/ml), whereas 16S rRNA mutations confer
higher levels of resistance to kanamycin (MIC > 80 µg/ml) and
frequently cross-resistance to amikacin. These eis mutants also
displayed increased levels of AAC activity, hence demonstrating
that Eis was a novel class of AAC, highly divergent from all
other previously known AACs. Eis is capable of acetylating
kanamycin more efficiently than amikacin, and streptomycin
was not found to be a substrate of Eis (Zaunbrecher et al.,
2009). From then on, detection of mutations in eis promoter has
become a relevant assay in clinical microbiology laboratories for
determining susceptibility to kanamycin (Georghiou et al., 2012);
the diagnostic and clinical implications of these tests are beyond
the scope of this review.
Formation of stable hexamers by Eis is required for its AAC
activity (Ganaie et al., 2011; Anand and Sharma, 2018), which
can acetylate multiple amine groups of different AG antibiotics,
including netilmicin, sisomicin, neamine, ribostamycin,
paromomycin, neomycin B, kanamycin, amikacin, tobramycin
and hygromycin, resulting in mono-, di-, tri, and tetraacetylated
products (Chen et al., 2011; Houghton et al., 2013a), being able
to use not only acetyl-CoA but also other acyl-CoA derivatives
(Chen et al., 2012a). The Eis protein works by a random-
sequential bisubstrate mechanism of acetylation (Tsodikov et al.,
2014). Interestingly, Eis is also able to acetylate capreomycin,
a polypeptide second-line antituberculosis drug commonly
used in the treatment of MDR tuberculosis infections (Reeves
et al., 2013). Several metal ions such as Au3+, Cd2+ and Zn2+
inhibited Eis activity in vitro (Li et al., 2015).
Other mycobacterial species such as M. smegmatis and
M. abscessus have ortholog (and even paralog) eis genes, although
the Eis proteins have distinct biochemical features and impact on
AG susceptibility in comparison with Eis ofM. tuberculosis (Chen
et al., 2012b; Rominski et al., 2017). For example, M. abscessus
has two eis genes, and the deletion of one (but not the other
one) resulted in altered AG susceptibility (Rominski et al., 2017;
Luthra et al., 2018). Consistently with these findings, mutational
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BOX 2 | Discovery and characterization of enhanced intracellular survival (Eis) protein of M. tuberculosis.
A genome wide investigation of the ability of M. tuberculosis for infecting macrophages resulted in the identification of a coding sequence that, once cloned in the
non-pathogenic M. smegmatis species, conferred capacity for infecting the human macrophage-like cell line U937. This gene was named eis (Rv2416c in the
M. tuberculosis genome; Cole et al., 1998) for enhanced intracellular survival (Wei et al., 2000), and was detected only in pathogenic species of mycobacteria. The
promoter of the eis gene is similar to consensus E. coli sigma-70 dependent promoters (Roberts et al., 2004) and it is recognized by M. tuberculosis SigA sigma
factor (Wu et al., 2009). The Eis protein was found to be mostly hydrophilic, but having a hydrophobic N-terminal end, so that it could be found in the cytosolic but
also in other cell fractions such as the membrane, cell wall or among the secreted proteins of M. tuberculosis (Dahl et al., 2001). In fact, antibodies against Eis could
detect this protein in the sera of tuberculosis patients (Dahl et al., 2001) and in the cytoplasm of infected macrophages (Samuel et al., 2007). Also, it was found that
Eis protein, directly added to cultures of human monocytes, modulated the secretion of pro-inflammatory cytokines in a similar way to that found in M. tuberculosis
infected cells (Samuel et al., 2007), hence suggesting a role of Eis as an effector protein. Further studies demonstrated that Eis inhibits the extra-cellular
signal-regulated kinase 1/2 (ERK1/2) and JAK pathways, and in consequence it inhibited the production of TNF-alpha and IL-4, and stimulated the production of
IFN-gamma and IL-10 (Lella and Sharma, 2007). The effect of Eis in increasing production of IL-10 was found to be related to Eis-mediated acetylation of histone
H3, which binds the promoter of the human IL-10 gene (Duan et al., 2016). Hence, by disturbing cross-regulation of T-cells and impairing TH1 and TH2 response,
Eis could mediate M. tuberculosis pathogenicity (Lella and Sharma, 2007). In fact, an isolate of the Beijing family (which are more transmissible and virulent than
other M. tuberculosis genetic lineages (Hanekom et al., 2011) was found to contain elevated levels of Eis protein, mediated by increased expression of SigA (Wu
et al., 2009). Other key factors in host immune response to tuberculosis are also mediated by Eis, which increased production of ROS and consequently modulated
processes such as autophagy, inflammation, and cell death (Shin et al., 2010). These processes are started by Eis-dependent acetylation of dual-specificity
phosphatase-16 (DUSP16)-mitogen-activated protein kinase phosphatase-7 (MKP-7), which dephosphorylates the JNK protein leading to its inactivation (Kim et al.,
2012; Yoon et al., 2013). Other studies have revealed the activity of Eis for acetylating arylalkylamines such as histamine, octopamine, or tyramine, suggesting novel
roles for this protein in M. tuberculosis pathogenicity (Pan et al., 2018).
changes in the amino acid residues lining the substrate binding
site of M. tuberculosis Eis altered its substrate specificity (Jennings
et al., 2013).
It is important to note that in M. tuberculosis, transcription
of the eis gene is activated by the regulator WhiB7 (Reeves
et al., 2013). Mutations in the promoter of whiB7 gene
that led to increase in the mRNA of this gene resulted
in increased expression of eis gene, along with other genes
such as rv1258c (encoding the Tap efflux pump; Ainsa et al.,
1998), hence resulting in cross resistance to several drugs
including kanamycin (mediated by Eis protein) or streptomycin
(mediated by Tap efflux pump). Similarly, in M. abscessus, WhiB7
controlled the expression of one of the two eis genes in this
species and also that of the erm(41) gene, which encodes a
ribosomal methyltransferase that by altering target structure
is associated with resistance to macrolide antibiotics (Pryjma
et al., 2017; Luthra et al., 2018). Subinhibitory concentrations
of clarithromycin induced the whiB7 gene and consequently
decreased Eis-mediated susceptibility to AGs, such as amikacin
that is currently used in the treatment of M. abscessus infections
(Pryjma et al., 2017).
Aminoglycosides and Beyond. . .
The unusual properties of Eis acetyltransferase include its
capability for acetylating peptides and proteins (Kim et al., 2012;
Houghton et al., 2013b; Yoon et al., 2013), in contrast with
other AACs. The M. tuberculosis nucleoid-associated protein
HU (encoded by Rv2986c gene) can be acetylated by Eis on
multiple lysine residues, hence decreasing its ability to interact
with DNA, and altering its DNA compactation activity (Ghosh
et al., 2016; Green et al., 2018). Overexpression of Eis led
to a hyperacetylation of HU protein, and consequently, to a
decompactation of the genome (Ghosh et al., 2016). The reverse
effect (condensation of relaxed DNA) could be reached through
the deacetylation of HU protein, which is mediated by a Sir2
family protein from M. tuberculosis encoded by the Rv1155c
gene (Anand et al., 2017; Green et al., 2018). Controlling the
architecture of DNA is a key process in any bacteria, and so, the
HU protein is essential for M. tuberculosis. In fact, inhibitors of
HU have been discovered (Bhowmick et al., 2014), which could
act in synergy with potential inhibitors of Eis, as described in the
next section.
Finding Inhibitors of Eis Protein
The crystal structure of M. tuberculosis Eis protein was
determined by several groups (Chen et al., 2011; Kim et al.,
2012), which has been useful for determining docking properties
of potential inhibitory compounds; also, its comparison with
the crystal structure of M. smegmatis Eis protein revealed
several distinct structural features that may account for the
biochemical and substrate differences between the two proteins
(Kim et al., 2014). A first screening of potential inhibitors of
Eis from M. tuberculosis resulted in the identification of 25
molecules (including the antiseptic chlorhexidine) that inhibited
Eis with IC50 values in the low micromolar range. In addition,
this inhibition was specific to the M. tuberculosis Eis protein,
since these molecules could not inhibit significantly AACs from
AAC(2′), AAC(3), and AAC(6′) families (Green et al., 2012), nor
Eis protein from Bacillus anthracis (Green et al., 2015a). Later
studies revealed the presence of eis-like genes in many pathogenic
and non-pathogenic bacteria (remarkably, many mycobacterial
species have two or even three paralogs of the eis gene), and
chlorhexidine was capable of inhibiting (to different levels) all
Eis proteins that were capable of acetylating AGs (Green et al.,
2015b).
A second screening of a larger collection of small-molecule
compounds resulted in the identification of several families of
compounds capable of inhibiting Eis activity. These contained
diverse chemical scaffolds (Garzan et al., 2016a,b, 2017; Willby
et al., 2016; Ngo et al., 2018). Besides, these inhibitors were
highly selective for Eis, and did not inhibited AACs from other
families (Garzan et al., 2016b). More importantly, as these
inhibitors bound in the AG pocket of the Eis protein, they
were able to reverse kanamycin resistance of a M. tuberculosis
isolate (Garzan et al., 2016b; Willby et al., 2016; Ngo et al., 2018).
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Some of these inhibitors, such as those based on a pyrrolo[1,5-
a]pyrazine scaffold, also lacked any toxicity on mammalian cell
lines (Garzan et al., 2017).
OTHER AMINOGLYCOSIDE-MODIFYING
ENZYMES IN MYCOBACTERIA
Genome-wide analysis of M. tuberculosis genome identified
only one other potential AAC (encoded by the Rv1347c gene),
although such enzymatic activity could not be detected on the
recombinant protein (Draker et al., 2003). Later studies related
the product of the Rv1347c gene with a role in the synthesis of
mycobactin, the mycobacterial siderophore (Card et al., 2005).
Leaving apart AACs, only a few reports of other classes
of aminoglycoside-modifying enzymes have been done in
mycobacteria. An APH enzyme of the APH(3′′) family,
conferring resistance to the AG streptomycin only, has been
characterized in M. fortuitum (Ramon-Garcia et al., 2006) and
M. abscessus (Dal Molin et al., 2018; Luthra et al., 2018); the
latter species encodes up to 11 additional putative APH enzymes
(Ripoll et al., 2009). Furthermore, a putative APH of the APH(3′)
class, encoded by the Rv3168 gene of M. tuberculosis, was
identified and expressed as a recombinant enzyme in E. coli, being
related to kanamycin phosphotransferase activity (Ahn and Kim,
2013).
BACK TO THE START POINT: Eis IN
M. fortuitum
We started this review referring to previous work that has shown
that crude extracts of M. fortuitum harbored AAC activity having
gentamicin, tobramycin, netilmicin and its derivatives 2′-N-
ethyl- and 6′-N-ethyl-netilmicin, kanamycin A and kanamycin
B as substrates. So far, the only AG acetyltransferase identified
in this species has been AAC(2′)-Ib (Ainsa et al., 1996),
which cannot explain the acetyltransferase activity against
kanamycin A and 2′-N-ethyl-netilmicin detected in M. fortuitum
crude extracts. Later studies characterized Eis AAC in diverse
mycobacterial species, but no report were been done on a putative
Eis protein in M. fortuitum. In view of the universal presence
of Eis proteins in mycobacteria, and its activity as AAC, we
hypothesized that M. fortuitum could also have a putative Eis
protein that would be responsible for the acetyltransferase activity
against kanamycin A and 2′-N-ethyl-netilmicin detected in crude
extracts of this species, as it was reported earlier (Hull et al., 1984;
Ainsa et al., 1996).
Thus, we first ascertained the existence of an eis gene in the
genome of M. fortuitum (Ho et al., 2012), which presented a 94%
of identity with respect to the one reported in M. tuberculosis;
the sequence of both Eis proteins from M. tuberculosis and
M. fortuitum also presented high levels of identity (Figure 1).
We designed two oligonucleotides for amplifying specifically a
DNA fragment from M. fortuitum genome containing eis gene.
This DNA fragment was subsequently cloned in pMV261 vector
(Stover et al., 1991), which expresses genes constitutively under
the control of the hsp60 gene promoter, resulting in plasmid
pFS2. Given that this plasmid still contains the Tn903-derived
aminoglycoside-3′-phosphotransferase (aph) gene (present in
the original pMV261 cloning vector) conferring kanamycin
resistance as selection marker, we anticipated that M. smegmatis
strains harboring pMV261 vector or its derivatives would be
intrinsically resistant to kanamycin A; this would prevent
from determining whether this antibiotic is a substrate of the
M. fortuitum Eis protein. Additionally, the selection marker
could have cross-effect with other AGs and thus interfering with
the resistance phenotype conferred by eis gene. To circumvent
these problems, we generated a derivative of pFS2 through the
disruption of the aph gene with the ampicillin resistance cassette
(bla gene) from pGEM R©-T easy (Promega). The resistance to
2′-N-ethylnetilmicin conferred by eis gene, as demonstrated for
the parental plasmid pFS2 (see Table 1) was used as resistance
marker for transformant selection and plasmid maintenance.
This process resulted in plasmid pEAC which contains the
M. fortuitum eis gene and no other determinant of AG resistance.
The three plasmids [original empty vector pMV261 as a
control, and the two plasmids (pFS2 and pEAC) containing
M. fortuitum eis gene] were introduced in M. smegmatis mc2 155
in order to over-express the ortholog eis gene from M. fortuitum
and to elucidate its hypothetical implication in AG susceptibility.
The antibiotic susceptibility assay was made, based on a double
dilution protocol with the addition of resazurin dye (Palomino
et al., 2002).
We observed that plasmids pFS2 and pEAC produced
detectable changes in AG susceptibility of M. smegmatis mc2 155,
which can be attributed to the expression of the plasmid-borne
M. fortuitum eis gene. The major shift in the MICs was detected
for 2′-N-ethylnetilmicin (Table 1), since the MIC increased from
3.12 to 6.25 µg/ml in the control strains to 50–100 µg/ml in the
strains containing M. fortuitum Eis, accounting for a 8- to 32-fold
increase; similar changes were observed for 6′-N-ethylnetilmicin
(8-fold increase in the MIC). A moderate decrease in the
susceptibility to kanamycin A (fivefold), hygromycin (twofold to
fourfold) and gentamicin (twofold to fourfold) was also observed.
Finally, slight changes (twofold) in the MICs were detected for
kanamycin B and capreomycin; this finding is consistent with
previous reports on the activity of M. tuberculosis Eis against
capreomycin (Reeves et al., 2013). The levels of susceptibility
to the AGs amikacin, streptomycin and spectinomycin, and
to other non-AG compounds tested (isoniazid, rifampicin,
ethambutol, ciprofloxacin, tetracycline, chloramphenicol) were
not altered significantly by the presence of the plasmid-encoded
eis gene (Table 1 and data not shown), suggesting that either
these antimicrobials are not substrates of the Eis enzyme or
the corresponding acetylations (if any) might just not affect
antibacterial activity.
CONCLUDING REMARKS
The presence and activity of AAC(2′)-I and Eis AACs in
mycobacteria have clearly demonstrated that their primary role
is little related with susceptibility to AGs.
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FIGURE 1 | Comparison of the amino acid sequences of Eis proteins from M. fortuitum and M. tuberculosis. Symbols under the sequence alignment: Asterisks (∗)
indicate positions with identical amino acid in both proteins. Colons (:) indicate positions which have amino acids with strongly similar properties. Periods (.) indicate
positions which have amino acids with weakly similar properties.
TABLE 1 | MICs (µg/ml) of antibiotics of different structural families in the
M. smegmatis mc2 155 strains that overexpress eis gene from M. fortuitum.
Strain M. smegmatis mc2 155
Plasmid None pMV261 pFS2 pEAC
Marker gene on plasmid None aph aph bla
M. fortuitum eis gene − − + +
Gentamicin 0.78-1.56 0.78 3.12 3.12
2′-N-ethyl netilmicin 6.25 3.12–6.25 50–100 50
6′-N-ethyl netilmicin 3.12 3.12 3.12–6.25 25
Kanamycin A 1.56 >100 >100 7.8
Kanamycin B 6.25 >100 >100 12.5
Hygromycin 15.6 15.6 31.2–62.5 62.5
Amikacin 0.39 0.39 0.39 0.39
Capreomycin 1.95 1.95 3.9 3.9
Streptomycin 0.25 0.25 0.25 0.25
Spectinomycin 62.5 31.2–62.5 62.5 62.5
The values separated by a dash indicate that growth was detected in both
concentrations. The range of antibiotic concentrations spanned from 0.78 µg/ml to
100 µg/ml, and from 0.25 µg/ml to 125 µg/ml; a twofold difference in the MIC was
not considered as significant. aph: aminoglycoside 3′-phosphotransferase from
Tn903; bla: beta-lactamase.
In the case of AAC(2′)-I enzymes, its presence
in phylogenetically distant genera as Providencia and
Mycobacterium remains to be an evolutionary mystery.
In contrast with this restricted distribution of AAC(2′)-I
enzymes among bacteria, Eis enzymes seem to be more
widely distributed, being present even in non-pathogenic and
environmental species, which suggest a general function of
Eis-like enzymes in bacterial metabolism, and virtually excludes
any potential selection of eis genes due to the use of AGs, or its
horizontal transfer from other species.
It is clear that in mycobacteria ribosomal modifications
constitute the major mechanism of AG resistance, given that
only one or two copies of ribosomal RNA operons are
present in these species, hence making likely the acquisition
of mutations conferring high levels of AG resistance. Then,
AAC(2′)-I enzymes only contribute modestly to innate low level
susceptibility to AGs, and despite other roles have been suggested
in the literature for mycobacterial AAC(2′)-I enzymes, their
relevance as potential drug targets is still modest, especially
in comparison with Eis acetyltransferase. The contribution
of Eis acetyltransferase to virulence of M. tuberculosis, and
the finding that Eis is related with resistance to kanamycin
(a second line drug for the treatment of tuberculosis) in
clinical isolates has greatly attracted the attention and promoted
the interest in developing Eis inhibitors. In some way, Eis
inhibitors would fall into the class of anti-virulence and anti-
resistance mechanisms compounds, which is a trending topic
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in the age of antimicrobial resistance. Globally, antimicrobial
resistance is a major public health threat, and multi and
extensively drug resistant (MDR, XDR) tuberculosis is a case
of particular concern, so progress and major advances that
can be expected from the coming years will be greatly
welcomed.
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